These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 16834832

  • 41. Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.
    Lin HL, Hsu YT, Liu CY, Chen CH, Hsiao MC, Liu YL, Shen WW, Hsiao CF, Liu SI, Chang LH, Tang HS, Lai HL, Lin PS, Lin KM, Tsou HH.
    Int Clin Psychopharmacol; 2013 Nov; 28(6):339-45. PubMed ID: 23881184
    [Abstract] [Full Text] [Related]

  • 42. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS, Cooper JA, Huusom AK, Hindmarch I.
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [Abstract] [Full Text] [Related]

  • 43. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
    Wade A, Gembert K, Florea I.
    Curr Med Res Opin; 2007 Jul; 23(7):1605-14. PubMed ID: 17559755
    [Abstract] [Full Text] [Related]

  • 44. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A.
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [Abstract] [Full Text] [Related]

  • 45. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 46. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 47. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
    Stein DJ, Andersen EW, Lader M.
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):33-8. PubMed ID: 16014329
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
    Möslinger-Gehmayr R, Zaninelli R, Contu A, Oberhoff C, Gutschow K, Schindler AE, Staab HJ.
    Zentralbl Gynakol; 2000 Jan; 122(4):195-202. PubMed ID: 10795116
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [Abstract] [Full Text] [Related]

  • 53. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

  • 54. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R, da Silva Telles RM, Alves TC, Andrei AM, Rays J, Iosifescu DV, Wajngarten M.
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [Abstract] [Full Text] [Related]

  • 55. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 56. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Dec; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 57. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 58. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G, SAD 388 Study Group.
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [Abstract] [Full Text] [Related]

  • 59. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG, Lunde M, Lindberg L, Undén M, Dissing S, Bech P.
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [Abstract] [Full Text] [Related]

  • 60. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.